CN101953847B - Application of zinc hydroxide in preparation of anti-cancer drugs - Google Patents
Application of zinc hydroxide in preparation of anti-cancer drugs Download PDFInfo
- Publication number
- CN101953847B CN101953847B CN2009100893212A CN200910089321A CN101953847B CN 101953847 B CN101953847 B CN 101953847B CN 2009100893212 A CN2009100893212 A CN 2009100893212A CN 200910089321 A CN200910089321 A CN 200910089321A CN 101953847 B CN101953847 B CN 101953847B
- Authority
- CN
- China
- Prior art keywords
- zinc hydroxide
- zinc
- preparation
- application
- hydroxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides application of a zinc hydroxide compound in preparation of anti-cancer drugs, in particular in the way of treating liver cancers. Through a zoology test, the zinc hydroxide has obvious anti-cancer effect on the liver cancer cells of mice and low toxic and side effects.
Description
Technical field
The present invention relates to a kind of chemical compound field of medicaments, specifically, relate to the application of a kind of zinc hydroxide chemical compound in the preparation cancer therapy drug.
Background technology
Cancer has become global persistent ailment, seizes millions of patient's life every year, and hepatocarcinoma is again the most dangerous cancer, is called as incurable disease, and active drug is very few.
Zinc hydroxide, chemical formula Zn (OH)
2, molecular weight 99.38.Colourless rhomboidal crystal.Density 3.053g/cm
3, be insoluble in water.It is amphoteric hydroxide.Be dissolved in strong acid and generate zinc salt.Be dissolved in highly basic and generate zincate.It adds an amount of strong base solution by zinc solution and makes.
Summary of the invention
The purpose of this invention is to provide the application of a kind of zinc hydroxide chemical compound in the preparation cancer therapy drug.
The present invention provides the application of a kind of zinc hydroxide chemical compound in the preparation cancer therapy drug.
Be particularly suitable for being used to treat hepatocarcinoma.
Zinc hydroxide of the present invention can adopt zinc sulfate or other zinc salts and alkali reaction, and dehydration is processed through seasoning then.
Mostly zinc hydroxide of the present invention is Powdered, generally reaches in the not superheated environment and preserves in dry, lucifuge.
Zinc hydroxide of the present invention can adopt zinc salt (such as zinc sulfate or zinc chloride) solution under stirring with adjusting PH with base to 8-9, leave standstill, collecting precipitation, 100-120 ℃ of oven dry in baking box obtains the zinc hydroxide powder.
Zinc hydroxide of the present invention can add medically acceptable pharmaceutic adjuvant and process various peroral dosage forms according to the conventional method of this area, such as capsule, tablet or pill, is preferably capsule.
The general patient's consumption per day of recommending is the 60mg/kg body weight, and is oral, also can abide by doctor's advice.
The inventor finds that in research process zinc hydroxide has tangible antitumaous effect, through zoology test, the rat liver cancer cell is had tangible antitumaous effect, and toxic and side effects is low.
The specific embodiment
Following examples are used to explain the present invention, but are not used for limiting scope of the present invention.
Embodiment 1
The preparation process of zinc hydroxide: earlier zinc sulfate is dissolved in distilled water; Solution is stirred well to nothing deposition, no granule, under stirring, transfers pH to 9, and then stirred 20 minutes with sodium hydroxide solution; Leave standstill to deposition decline; When clear layer appears in the upper strata, drip a 1-2 toward clear layer and drip sodium hydroxide solution, alkali takes place then still must add till do not have a deposition as also having deposition.Hold over night, supernatant is removed in inferior daily latex tubing siphon, and with filter cloth or centrifugal collecting precipitation, 100 ℃ of bakings are collected in the sealed container to doing in baking box.
Capsular preparation process: the zinc hydroxide powder is mixed with 10: 1 with starch, cross 60 mesh sieves, stir, pour capsule (capsule shells is processed by sodium carboxymethyl cellulose gelatin and glycerol) into and fill in the mould, the fill capsule, polishing, packing promptly gets.
Test Example 1 determination of acute toxicity
(1) material
1. medicine: zinc hydroxide dry powder, lot number: 030916, face with preceding and be mixed with suspension with 0.5-1.0% Carboxymethyl cellulose sodium (CMC-Na), subsequent use.
2. laboratory animal: the heavy 20g ± S1g of Kunming mouse, the male and female dual-purpose, by the animal center supply of Fujian medical university, the animal quality certification number: the accurate 002-04 of the real kinoplaszm in Fujian.
(2) method and result
1. exploration dosage range
Get some, 12 hours mices of fasting are divided into some groups at random; Every group 3, at first 10 multiple doses by the median dose (0.4g/kg) of effective dose are that 4.0g/kg (0.1g/ml zinc hydroxide, 0.4ml/10g body weight) irritates stomach; Observed 72 hours; The result does not see dead mouse, and repeated trials three times comes to the same thing.Improve dosage subsequently, dosage is brought up to 16.0g/kg, do not see dead mouse yet.
2. maximum tolerated dose confirms
For improving the hydroxide zinc concentration, improve the suspension of medicine, therefore the concentration with CMC-Na is increased to 1.0% by 0.5%, simultaneously the hydroxide zinc concentration is brought up to 0.2g/ml.The selection of animal, route of administration is the same.Select 20 of mices, irritate gastric capacity and reach 1.0ml/10g body weight (the maximum tolerance capacity of a gastric infusion of mice), dosage is 20.0g/kg; After irritating stomach, mouse web portion shows slightly expansion, and it is slightly slow to take action; Torpescence, through behind the 10-20min, situation makes moderate progress; Observe a week continuously, animal does not produce death.At viewing duration, mice does not have death, but sees that its hair is more sparse, tarnish, and mentioning the visible root of afterbody has the milky Excreta to adhere to, and the prompting mice has diarrhoea.Repeated trials three times comes to the same thing, and the LD of zinc hydroxide gastric infusion is described
50Greater than 20.0g/kg.
(3) conclusion
The zinc hydroxide acute toxicity is little, and the maximum tolerated dose of mouse stomach administration is greater than 20.0g/kg.
The anticancer research of Test Example 2 zinc hydroxide
(1) material
1. medicine; Zinc hydroxide, lot number: 030916, face with preceding and be mixed with suspension with 0.5% Carboxymethyl cellulose sodium (CMC-Na), subsequent use.
2. laboratory animal: the heavy 20g ± S1g of Kunming mouse, the male and female dual-purpose, by the animal center supply of Fujian medical university, the animal quality certification number; The accurate 002-04 of the real kinoplaszm in Fujian.
3. tumor strain: mice transplantability ascitic type liver cancer (H
22), provide by Medical University Of Fujian's clinical pharmacology institute.
(2) method and result
1. solid type transplanted tumor is inoculated and dose regimen: under aseptic condition, get well-grown Murine Ascitic Hepatoma Cells strain (H
22) be mixed with 4.5-6.0 * 10
6The normal saline suspension of/ml concentration, it is subcutaneous to be inoculated in the right side of mice axillary fossa, and 0.2ml/ is only.Inoculate back 24 hours mices and divide 5 groups at random, 10 every group, promptly zinc hydroxide low, in and high dose group, respectively ig zinc hydroxide 0.6,1.2,1.8gkg
-1D
-1* 10d; Positive controls, ipd
-1* 10d, negative control group ip equal-volume normal saline.Mice is respectively organized in execution in 24 hours after drug withdrawal, weighs, and peels off the tumor piece, claims that tumor is heavy and is calculated as follows tumor control rate:
2. experimental result
Zinc hydroxide is low, in and high dose be 0.6g/kg, 1.2g/kg and 1.8g/kg gastric infusion, once a day, continuous 10 days, all can obviously suppress mice transplanted solid tumor tumor (H
22) growth, heavy and inhibition rate of tumor growth of tumor and negative control group relatively have statistical significance (seeing table 1), during the medication, animal generally in order.
Table 1 zinc hydroxide is irritated stomach (ig) to mouse bearing liver cancer (H
22) inhibitory action (x ± s, n=10)
(3) conclusion
The zinc hydroxide gastric infusion is to mice transplantability ascites hepatoma cells strain (H
22) tumor-bearing mice has the therapeutic trial effect.
Though, the present invention has been done detailed description in the preceding text with general explanation and specific embodiments, on basis of the present invention, can to some modifications of do or improvement, this will be apparent to those skilled in the art.Therefore, these modifications or the improvement on the basis of not departing from spirit of the present invention, made all belong to the scope that requirement of the present invention is protected.
Claims (1)
1. the application of zinc hydroxide chemical compound in preparation treatment liver-cancer medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100893212A CN101953847B (en) | 2009-07-15 | 2009-07-15 | Application of zinc hydroxide in preparation of anti-cancer drugs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100893212A CN101953847B (en) | 2009-07-15 | 2009-07-15 | Application of zinc hydroxide in preparation of anti-cancer drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101953847A CN101953847A (en) | 2011-01-26 |
| CN101953847B true CN101953847B (en) | 2012-05-30 |
Family
ID=43481605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100893212A Expired - Fee Related CN101953847B (en) | 2009-07-15 | 2009-07-15 | Application of zinc hydroxide in preparation of anti-cancer drugs |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101953847B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110642648A (en) * | 2019-11-08 | 2020-01-03 | 上海永通生态工程股份有限公司 | Preparation method of micronutrient zinc-manganese chelate |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080038368A1 (en) * | 2006-01-27 | 2008-02-14 | Yale University | Fast acting inhibitor of gastric acid secretion |
| CN101125150A (en) * | 2007-08-13 | 2008-02-20 | 王小丁 | Application of nanometer zinc oxide in preparing medicine for treating malignant tumor |
-
2009
- 2009-07-15 CN CN2009100893212A patent/CN101953847B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080038368A1 (en) * | 2006-01-27 | 2008-02-14 | Yale University | Fast acting inhibitor of gastric acid secretion |
| CN101125150A (en) * | 2007-08-13 | 2008-02-20 | 王小丁 | Application of nanometer zinc oxide in preparing medicine for treating malignant tumor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101953847A (en) | 2011-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200826953A (en) | Agonist for healing living organisms | |
| KR950008767B1 (en) | Novel pharmacentical use of ebselen | |
| CN101953847B (en) | Application of zinc hydroxide in preparation of anti-cancer drugs | |
| CN102475698A (en) | Application of salvianolic acid L in preparation of medicines used for treating tumor | |
| JPS6379824A (en) | Carcinostatic agent | |
| CN101129387A (en) | New medical use of cucurbitacin in treating cancer | |
| CN102058608A (en) | New application of glucosamine in treating dental ulcer | |
| CN101541717B (en) | A trans-cinnamic acid derivative, its preparation method and the use | |
| CN100526324C (en) | Process for the preparation of trans- or cis-diammoniumdichlorodihydroxyplatinum(IV) salts and derivatives and their use for the preparation of pharmaceutical active agents | |
| JP2018138582A (en) | Amylase-activity-inhibiting composition containing chito-oligosaccharide | |
| CN103224572A (en) | Preparation of alginic acid cerium complex and application of alginic acid cerium as antiemetic drugs | |
| CN103142909B (en) | Orally traditional Chinese medicine composition for treating lung cancers | |
| WO2019201268A1 (en) | Drug used for preventing and/or treating pain and/or fever, combination product, and use thereof | |
| CN109045052A (en) | For treating pharmaceutical formulation and the application of colon cancer | |
| JP6533866B2 (en) | Use of dihydroxyacetone for producing antineoplastic agents | |
| CN104523698B (en) | Application of the hederagenin in preparation anti-endometrial cancer cell HEC-1 tumour medicine | |
| WO1999056738A1 (en) | Use of triclosan for the treatment of helicobacter pylori infections | |
| CN111467367B (en) | Plant monomer composition for inhibiting tumor cell growth and preparation method and application thereof | |
| CN102716465B (en) | Pharmaceutical composite for treating tumor and preparation method of pharmaceutical composite | |
| CN109846876B (en) | Application of lignan compound in resisting tumor and preparation of medicine thereof | |
| CN100421672C (en) | Compound lentinan preparation for antitumour and its preparing method | |
| CN106727631A (en) | Application of the Ginsenoside Rh4 in antineoplastic is prepared | |
| CN102018690A (en) | Anti-tumor medicament and application thereof | |
| JP2009084211A (en) | Composition for nerve cell activation | |
| CN104523699B (en) | Hederagenin is preparing the application in ovarian cancer resistance HO-8910PM tumour medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120530 Termination date: 20130715 |